Loading clinical trials...

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

A Phase II Study Evaluating the Preliminary Efficacy and Safety of ZG006 in Participants With Metastatic Neuroendocrine Prostate Cancer

NCT07024277•Suzhou Zelgen Biopharmaceuticals Co.,Ltd

View on ClinicalTrials.gov

Summary

This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.

Eligibility

Age

18 - 80 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Male Participants aged 18 to 80 years (inclusive);
•Advanced metastatic neuroendocrine prostate cancer;
•disease progression after at least one line of platinum-based systemic therapy or intolerance to toxicity;
•Measurable disease according to RECIST v1.1 criteria;
•Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

Exclusion Criteria

•Known positive test for human immunodeficiency virus (HIV) or hepatitis；
•Patients were deemed unsuitable for participating in the study by the investigator for any reason.

Locations (1)

Fudan university shanghai cancer center

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

August 1, 2025

Primary Completion Date

December 1, 2027

Completion Date

December 1, 2027

Last Updated

June 17, 2025

Enrollment

ESTIMATED participants

Conditions

Neuroendocrine Prostate Cancer

Interventions

ZG006

BIOLOGICAL

Contacts

Shangdi Ning

CONTACT

+86-0512-57309965 ningsd@zelgen.com

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

NCT02709889

Malignant MelanomaMedullary Thyroid Cancer+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions